Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.62 USD | +5.44% | +3.69% | +14.93% |
02:00pm | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
May. 13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Financials (USD)
Sales 2024 * | 26.58M | Sales 2025 * | 78.61M | Capitalization | 178M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -4M | EV / Sales 2024 * | 6.69 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.26 x |
P/E ratio 2024 * |
-5.45
x | P/E ratio 2025 * |
-24.7
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.07% |
Latest transcript on Capricor Therapeutics, Inc.
1 day | +5.44% | ||
1 week | +3.69% | ||
Current month | +6.64% | ||
1 month | -5.23% | ||
3 months | +55.68% | ||
6 months | +82.47% | ||
Current year | +14.93% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 5.64 | +5.82% | 505,314 |
24-05-15 | 5.33 | +2.50% | 284,300 |
24-05-14 | 5.2 | -4.41% | 667,284 |
24-05-13 | 5.44 | +2.64% | 193,872 |
24-05-10 | 5.3 | -2.21% | 233,835 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.93% | 178M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.32% | 22.28B | |
-5.71% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- CAPR Stock